Scholarlink

Abstract <p>Nicotinamide riboside (NR) a NAD<sup>+</sup> precursor.There is ample evidence in the literature for beneficial effectsof its peroral administration in cardiovascular, neurodegenerative,renal, hepatic, and some other diseases. Previously, we have advanceda hypothesis that intravenous NR administration exerts a cardioprotectiveeffect during doxorubicin anticancer chemotherapy. The present studywas aimed to assess the biocompatibility of various NR doses duringrepeated intravenous drug administration to Wistar rats. The dosestested were the following: 150, 300, 450, and 600 mg/kg matchingrespective cumulative doses of 900, 1800, 2700, and 3600 mg/kg.Under this administration regimen, NR biocompatibility was demonstratedfor the doses of 150, 300, and 450 mg/kg. Even at 450&#xa0;mg/kg, repeatedintravenous NR administration revealed no adverse effects on thecardiac parasympathetic ganglia of the autonomic nervous system.However, the dose of 600 mg/kg led to a number adverse side effects,including reduced cardiovascular efficiency, morphological and functional alterationsin the myocardium, liver and kidneys, as well as a higher deathrate and decreased exercise tolerance in rats.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Biocompatibility of Different Nicotinamide Riboside Doses Administered Intravenously to Rats

  • 期刊论文

  • 发表日期：

    2025年3月1日

查看全文
  • E. Yu. Podyacheva,
  • N. Yu. Semenova,
  • D. V. Mukhametdinova,
  • I. A. Zelinskaya,
  • L. A. Murashova,
  • A. V. Onopchenko,
  • E. V. Shchelina,
  • M. O. Martynov,
  • V. A. Dyachuk,
  • V. A. Zinserling,
  • Ya. G. Toropova

摘要

Abstract

Nicotinamide riboside (NR) a NAD+ precursor.There is ample evidence in the literature for beneficial effectsof its peroral administration in cardiovascular, neurodegenerative,renal, hepatic, and some other diseases. Previously, we have advanceda hypothesis that intravenous NR administration exerts a cardioprotectiveeffect during doxorubicin anticancer chemotherapy. The present studywas aimed to assess the biocompatibility of various NR doses duringrepeated intravenous drug administration to Wistar rats. The dosestested were the following: 150, 300, 450, and 600 mg/kg matchingrespective cumulative doses of 900, 1800, 2700, and 3600 mg/kg.Under this administration regimen, NR biocompatibility was demonstratedfor the doses of 150, 300, and 450 mg/kg. Even at 450 mg/kg, repeatedintravenous NR administration revealed no adverse effects on thecardiac parasympathetic ganglia of the autonomic nervous system.However, the dose of 600 mg/kg led to a number adverse side effects,including reduced cardiovascular efficiency, morphological and functional alterationsin the myocardium, liver and kidneys, as well as a higher deathrate and decreased exercise tolerance in rats.